Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty
Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with high affinity for dopamineD2 and D1 receptors and the serotonin transporter. It is unusual in that it controlsserotonin, dopamine, and glutamate neurotransmission concurrently, all of which havebeen impl...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
2022
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/96215/9/96215_Atypical%20antipsychotic%20Lumateperone.pdf http://irep.iium.edu.my/96215/ https://osf.io/preprints/africarxiv/26xec/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with high affinity for dopamineD2 and D1 receptors and the serotonin transporter. It is unusual in that it controlsserotonin, dopamine, and glutamate neurotransmission concurrently, all of which havebeen implicated in severe mental illness. Consider it a multi-targeted ligand andmultifunctional modulator of the serotoninergic system with possible precognitive,antipsychotic, antidepressant, and anxiolytic properties. While lumateperone has beenexplored as a new agent for schizophrenia therapy, it also provides a unique therapeuticoption for a range of other psychiatric and neurological diseases, including behaviouralsigns of dementia or Alzheimer's disease, sleep problems, and bipolar depression.Additionally, it had a better safety profile than placebo, with no significant extrapyramidalside effects, hyperprolactinemia, or changes in cardiometabolic or endocrinecharacteristics. Additional study is needed to validate and analyse lumateperone's1
effectiveness, as well as to identify prospective therapeutic targets. This article gives acomprehensive overview of the most notable results and potential future applications ofthis chemical in personalised medicine, particularly for neurodegenerative diseases |
|---|